Investors are bargain hunting in shares of housing contractor Installed Building Products Inc.(IBP), which saw its initial public offering price well below expectations late Wednesday.
The Columbus, Ohio-based company settled for a much smaller initial share sale than it had planned, as institutional investors involved in pricing the deal late Wednesday balked at the valuation the company had pitched. The IPO priced at $11 a share, versus the company�� forecast of $14 to $16. Further reducing the deal�� size, the company sold 17% fewer shares than expected.
But the shares opened up 12% in their trading debut Thursday, and extended gains later in the morning.
Installed Building Products��debut follows mixed performance from shares of some newly public building-products companies. Through Tuesday, siding manufacturer Ply Gem Holdings Inc.(PGEM)�� shares were down 39% from the offer price in its $381 May debut. Wood-products maker Boise Cascade Co.(BCC) was up 46% from its $284 million February IPO.
Top 5 Consumer Companies To Own For 2016: Halozyme Therapeutics Inc.(HALO)
Halozyme Therapeutics, Inc., a biopharmaceutical company, engages in the research, development, and commercialization of recombinant human enzymes that transiently modify tissue under the skin to facilitate injection of other therapies or correct diseased tissue structures for clinical benefits. The company primarily offers recombinant human hyaluronidase, an enzyme that degrades hyaluronan, which is a matrix component in the skin, and facilitates the dispersion and absorption of drugs and fluids. Its portfolio of products and product candidates are developed based principally on intellectual property covering the family of human enzymes known as hyaluronidases. The company also provides Ultrafast Insulin program, a Phase II clinical trial product for the treatment of diabetes mellitus; and Enhanze technology, a proprietary drug delivery platform for subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as sma ll molecules and fluids. It offers PEGPH20, a new molecular entity that is in Phase I trial for the systemic treatment of tumors; and HTI-501, a recombinant human proteinase, which is in Phase 1/2 clinical trial used for the treatment of edematous fibrosclerotic panniculopathy (cellulite). The company has collaborative partnerships with F. Hoffmann-La Roche, Ltd and Hoffmann-La Roche, Inc.; ViroPharma Incorporated; and Intrexon Corporation to apply Enhanze technology to the partners? biological therapeutic compounds. Halozyme Therapeutics, Inc. was founded in 1998 and is based in San Diego, California.
Advisors' Opinion:- [By Jayson Derrick]
Halozyme Therapeutics (NASDAQ: HALO) halted patient enrollment and dosing in its Phase 2 clinical trial of PEGPH20 based on a recommendation by the Data Monitoring Committee who argued that there may be a difference in the thomboembolic rate between the PEGPH20 patients and the non-treated group. Shares lost 27.26 percent, closing at $8.43.
- [By Sean Williams]
The EMA's Committee for Medicinal Products for Human Use, or CHMP, also played a big role in Halozyme Therapeutics' (NASDAQ: HALO ) huge Friday surge. The EMA's panel recommended Roche's Herceptin SC, which uses Halozyme's recombinant human hyaluronidase in a subcutaneous injection for patients with HER2-positive breast cancer. A typical infusion of Herceptin can take 30 to 90 minutes, whereas the subcutaneous injection can be delivered in a fraction of the time, two to five minutes. This new delivery method could save hospitalization time and money and improve patient comfort. It could also be a transformative approval for Halozyme.�
- [By Monica Gerson]
Halozyme Therapeutics (NASDAQ: HALO) shares dropped 2.04% to $8.12 after the company reported a clinical hold of PEGPH20 pancreatic cancer trial amid voluntary halt.
- [By Keith Speights]
Halozyme Therapeutics (NASDAQ: HALO ) isn't quite as close to commercialization. The company has a mid-stage study under way that combines its rHuPH20 hyaluronidase enzyme with a mealtime insulin analog. Halozyme's enzyme helps the insulin to be absorbed more quickly than it would normally.
Top 10 Building Product Stocks To Own Right Now: Arrium Ltd (ARRMF)
Arrium Limited is an international mining and materials company. The Company�� principal activities are mining and supply of iron ore and other steelmaking raw materials to steel mills internationally and in Australia; the manufacture and supply of mining consumables products globally; the manufacture and distribution of steel long products and recycling of ferrous and non-ferrous scrap metal. Its key businesses include Mining, Mining Consumables, Steel and Recycling. Arrium Mining is an exporter of hematite ore with operations in South Australia. Arrium Mining also supplies pelletised magnetite iron ore and some hematite lump iron ore to the Company�� integrated steelworks. Arrium Mining Consumables supplies resource companies with a range of key mining consumables, including grinding media, wire ropes and rail wheels. Arrium�� integrated Steel and Recycling include OneSteel Manufacturing, long products steel manufacturing business, and OneSteel Distribution. Advisors' Opinion:- [By MARKETWATCH]
LOS ANGELES (MarketWatch) -- Australian stocks rose modestly in early Tuesday trade, with the market reacting to a mixed batch of earnings. The S&P/ASX 200 (AU:XJO) added 0.2% to 5,391.80, with BHP Billiton Ltd. (AU:BHP) (BHP) rising 1.7% after its July-December profit almost doubled from a year earlier, beating forecasts. However, smaller rival Arrium Ltd. (AU:ARI) (ARRMF) added 2.5% after reporting a swing back to profit. Other miners got a bump up from rising commodity prices, as Newcrest Mining Ltd. (AU:NCM) (NCMGF) gained 2.3% and Fortescue Metals Group Ltd. (AU:FMG) (FSUMF) added 1.2%, though Oz Minerals Ltd. (AU:OZL) (OZMLF) slipped 0.4%. Shares of Coca-Cola Amatil Ltd. (AU:CCL) (CCLAF) slumped 5.1% after the drinks firm saw a more than 80% drop in 2013 profit, weighed by a writedown on its fruit-processing business. Packaging firm Amcor Ltd. (AU:AMC) (AMCRF) lost 4.6% after its fiscal-first-half profit fell by about a third.
Top 10 Building Product Stocks To Own Right Now: First Financial Corporation Indiana(THFF)
First Financial Corporation, through its subsidiaries, provides various financial services. Its deposit products include interest-bearing and non-interest-bearing demand deposits, savings accounts, time deposits, and certificates of deposit. The company?s loan portfolio comprises commercial, financial, and agricultural loans; residential loans; and consumer loans. It also provides mortgage lending; lease financing; trust account and depositor services; and insurance services, such as property and casualty insurance, surety bonds, employee benefit plans, life insurance, and annuities. The company operates 54 branches in west-central Indiana and east-central Illinois. First Financial Corporation was founded in 1984 and is headquartered in Terre Haute, Indiana.
Advisors' Opinion:- [By James E. Brumley]
What do Prospect Capital Corporation (NASDAQ:PSEC), Astec Industries, Inc. (NASDAQ:ASTE), and First Financial Corp. (NASDAQ:THFF) have in common? Not much, on the surface. In fact, were it not for something very specific to one particular person (me), they'd have nothing in common at all. This week though, THFF, ASTE, and PSEC all have at least one thing in common, and that's the fact that they're all going into my mental/hypothetical portfolio.
Top 10 Building Product Stocks To Own Right Now: GrubHub Inc (GRUB)
GrubHub, Inc., incorporated on May 10, 2013, is an online and mobile platform for restaurant pick-up and delivery orders. As of December 31, 2013, the Company processed more than 135,000 combined daily average grubs. The Company�� target market is primarily independent restaurants. The Company connects local restaurants with diners in more than 600 cities across the United States. It generates revenue primarily when diners place an order on its platform through the Company�� Websites, its mobile applications, third-party Websites or one of its listed phone numbers. On August 8, 2013, GrubHub Inc. acquired Seamless North America, LLC, Seamless Holdings Corporation (Seamless Holdings) and GrubHub Holdings Inc., pursuant to that certain Reorganization and Contribution Agreement, dated as of May 19, 2013, by and among GrubHub Inc., Seamless North America, LLC, Seamless Holdings, GrubHub Holdings Inc. and the other parties thereto (the Reorganization Agreement). The acquisition of GrubHub Holdings Inc. has been accounted for as a business combination.
GrubHub and Seamless Websites
The primary way diners access the Company�� platform is through www.grubhub.com and www.seamless.com. To use the Company�� Websites, diners enter their delivery address and are presented with local restaurants that provide takeout. Diners can further refine their search results using its search capability, enabling them to filter results across cuisine types, restaurant names, menu items, proximity, ratings and other criteria. Once diners have found what they are looking for, they place their orders using its menus, enabling them to discover food choices, select options and provide specific instructions on a dish-by-dish basis. Once an order is received, the Company transmits it to the restaurant, while saving the diners��preferences for future orders.
GrubHub and Seamless Mobile Apps
The Company offer diner�� access to its network through the Company�� mobile applicati! ons designed for iPhone, iPad and Android devices. Its mobile applications provide diners with the same functionality as its Websites, including restaurant discovery, search and ordering. For restaurants, mobile orders are received in the same way as its Website-based orders, and it charge the same commission for both.
GrubHub and Seamless Mobile Apps
The Company offers diner�� access to its network through its mobile applications designed for iPhone, iPad and Android devices. Its mobile applications provide diners with the same functionality as its Websites, including restaurant discovery, search and ordering. For restaurants, mobile orders are received in the same way as the Company�� Website-based orders.
Seamless Corporate Program
On the Seamless Platform, the Company provides a corporate program. Its corporate program offers employees a variety of food and ordering options, including options for individual meals, group ordering and catering, as well as tools that consolidate all food ordering into a single online account that enables companies to manage food spend. Its corporate tools provide consolidated ordering and invoicing.
Allmenus and MenuPages
Allmenus.com and MenuPages provide an aggregated database of approximately 275,000 menus from restaurants across all 50 states. The Websites are searchable by cuisine type, restaurant name, menu items and other criteria. For those restaurants whose menus are posted on allmenus.com or MenuPages and who are also part of its restaurant network, the Company provides a link from their menus to its Websites, through which diners can then place their orders.
OrderHub and Boost
The Company�� tablet solutions, OrderHub and Boost can electronically receive and display orders at the restaurant, providing operators with the capability to acknowledge receipt of the order and update the estimated completion time and status. OrderHub and Boost enables! the Comp! any to monitor orders through the takeout process (receipt, ready for pickup, on the way).
Restaurant Websites
The Company offers the restaurants in its network a Website design and hosting service. The Company processes the orders placed through these Websites through its platforms.
APIs
The Company has developed an application programming interface for third-party Websites to incorporate its order delivery platform, driving additional orders for the restaurants in the Company�� network.
Advisors' Opinion:- [By Jayson Derrick]
After pricing its IPO at $26, shares of GrubHub (NYSE: GRUB) began trading for the first time at $40 and closed the day at $34.00, up 30.77 percent.
Top 10 Building Product Stocks To Own Right Now: Mast Therapeutics Inc (MSTX)
Mast Therapeutics, Inc., formerly ADVENTRX Pharmaceuticals, Inc., incorporated in December 1995, is a development-stage company biopharmaceutical company focused on developing product candidates. The Company's product candidate is ANX-188, a rheologic, antithrombotic and cytoprotective agent that improves microvascular blood flow and has application in treating a range of diseases and conditions, such as complications arising from sickle cell disease. As of December 31, 2011, the Company also is developing ANX-514, a detergent-free formulation of the chemotherapy drug docetaxel. The Company offers ANX-188 (purified poloxamer 188), ANX-514 (docetaxel for injectable emulsion) and Exelbine (vinorelbine injectable emulsion). In April 2011, the Company acquired SynthRx, Inc. In February 2014, Mast Therapeutics Inc completed its acquisition of Aires Pharmaceuticals, Inc. Aires became a wholly-owned subsidiary of Mast Therapeutics.
ANX-188 (purified poloxamer 188)
ANX-188 is an aqueous solution of a purified form of poloxamer 188. Poloxamer 188 (P1880, is a nonionic, block copolymer that has been found to improve microvascular blood flow by reducing viscosity, particularly under low shear conditions, and by reducing adhesive frictional forces. The Company�� purified form of P188 (purified P188), which is the active ingredient in ANX-188, was designed to eliminate certain low molecular weight substances present in P188 (non-purified), which is primarily responsible for the moderate to moderately severe elevations in serum creatinine levels (acute renal dysfunction) observed in prior clinical studies of P188 (non-purified). Purified P188 has been evaluated in multiple clinical studies by a prior sponsor, including a 255-patient, phase III study.
ANX-514 (docetaxel for injectable emulsion)
ANX-514 is a detergent-free emulsion formulation of docetaxel, an intravenously-injected chemotherapy drug commonly used to treat solid tumors. Taxotere, a branded form! ulation of docetaxel, is approved to treat breast, non-small cell lung, prostate, gastric, and head and neck cancers. ANX-514 was designed to have clinically comparable release of docetaxel relative to Taxotere while eliminating the presence of polysorbate 80 and ethanol, both of which are used to solubilize docetaxel in the Taxotere formulation. The ANX-514 formulation solubilizes docetaxel using oil droplets consists of a combination of non-toxic excipients. Docetaxel is contained within these oil droplets and can be administered intravenously without using detergents as pharmaceutical vehicles. Once in central circulation, the emulsion is metabolized rapidly, leaving chemically-identical active ingredient to exert its cytotoxic effect. ANX-514 may reduce the incidence and severity of hypersensitivity reactions and delay the onset of fluid retention.
Exelbine (vinorelbine injectable emulsion)
Exelbine is an emulsion formulation of the chemotherapy drug vinorelbine. Navelbine, a branded formulation of vinorelbine, is approved in the United States to treat advanced non-small cell lung cancer as a single agent or in combination with cisplatin, and approved in the European Union to treat non-small cell lung cancer and advanced or metastatic breast cancer.
In August 2011, the Company received a complete response letter from the Food and Drug Administration (FDA) stating that it could not approve the Exelbine Non Disclosure Agreement (NDA) in its present form and that the bioequivalence study would need to be repeated because the authenticity of the drug products used in the bioequivalence trial could not be verified in accordance with FDA standards. However, the Company elected to discontinue independent development of Exelbine and as of December 31, 2011, the Company was seeking a partner or outside investor for the program to complete the necessary bioequivalence study.
The Company competes with GlaxoSmithKline, Provenge and Pfizer.
Advisors' Opinion:- [By James E. Brumley]
A little over a month ago, owning Mast Therapeutics, Inc. (NYSE: MSTX) was nothing but pure misery. Shares plunged from $0.63 to $0.43 in one day, when details of a dilutive public offering were unveiled. As is so often the case though, the market may have overshot with the selling effort that KO's MSTX. Though putting more shares 'out there' mathematically meant existing shareholders would have to share more of the company's upside with newcomers, what's slowly coming to light is that the inflow of new cash is still more advantageous to those prior shareholders; the company would progress little without it.
- [By John Udovich]
The start of 2014 shows that biotech is still a hot area with the sector along with small cap biotech stocks like AMAG Pharmaceuticals, Inc (NASDAQ: AMAG), Mast Therapeutics Inc (NYSEMKT: MSTX), Cell Therapeutics Inc (NASDAQ: CTIC), Imprimis Pharmaceuticals Inc (NASDAQ: IMMY) and TNI BioTech (OTCMKTS: TNIB) producing news or returns�plus Auspex Pharmaceuticals (NASDAQ: ASPX), Cara Therapeutics (NASDAQ: CARA), Egalet (NASDAQ: EGLT), Flexion Therapeutics (NASDAQ: FLXN) and Ultragenyx Pharmaceutical (NASDAQ: RARE) are among the (many�� planned biotech IPOs that have recently been announced publicly:
Top 10 Building Product Stocks To Own Right Now: Threshold Pharmaceuticals Inc.(THLD)
Threshold Pharmaceuticals, Inc., a biotechnology company, engages in the discovery and development of drugs targeting the microenvironment of solid tumors for patients living with cancer. The company?s products include TH-302, a novel drug candidate which is in Phase 1, Phase 1/2, and Phase 2 clinical trials for cancer. It has a license agreement with Eleison Pharmaceuticals, Inc. to develop and commercialize glufosfamide for the treatment of cancer in humans and animals. The company was founded in 2001 and is headquartered in Redwood City, California.
Advisors' Opinion:- [By James E. Brumley]
Stocks as a whole haven't gotten the new year off on the best foot, but that's not to say every equity out there is in trouble. Indeed, some small cap stocks may actually be doing well - and poised to do well for a while - specifically because larger companies are seeing their stocks struggle. To that end, traders looking for a bullish bright spot to start the new year may want to take a closer look at Amedica Corporation (NASDAQ:AMDA), Threshold Pharmaceuticals, Inc. (NASDAQ:THLD), and Aethlon Medical, Inc. (OTCMKTS:AEMD).
Top 10 Building Product Stocks To Own Right Now: Icahn Enterprises L.P. (IEP)
Icahn Enterprises L.P., through its subsidiaries, engages in investment, automotive, gaming, railcar, food packaging, metals, real estate, and home fashion businesses in the United States and internationally. Its Investment segment provides investment advisory, and administrative and back office services to the investment funds. The company�s Automotive segment offers powertrain energy, powertrain sealing and bearings, vehicle safety and protection, and aftermarket products for original equipment manufacturers. Icahn Enterprises L.P.�s Gaming segment owns and operates casino gaming properties. It has 9 casino facilities with 7,485 slot machines, 226 table games and 6,048 hotel rooms in Nevada, Mississippi, Indiana, Louisiana, New Jersey, and Aruba. The company�s Railcar segment designs, manufactures, sells, and leases hopper and tank railcars; custom designed railcar parts and other industrial products, primarily aluminum and special alloy steel castings; and provides r epair and maintenance services for railcar fleets. Icahn Enterprises L.P.�s Food Packaging segment produces and sells cellulosic, fibrous, and plastic casings for the processed meat and poultry industry. The company�s Metals segment collects, processes, and sells ferrous and non-ferrous metals, as well as processes and distributes steel pipe and plate products. Icahn Enterprises L.P.�s Real Estate segment engages in the rental of retail, office, and industrial properties; construction and sale of single-family and multi-family homes, lots in subdivisions and planned communities, and raw land for residential development; and golf and resort activities. The company�s Home Fashion segment manufactures, sources, distributes, markets, and sells home fashion consumer products, including bed, bath, basic bedding, and kitchen textile products. Icahn Enterprises G.P. Inc. serves as the general partner of the company. Icahn Enterprises L.P. was founded in 1987 and is headquartered in New York, New York.
Advisors' Opinion:- [By Robert Rapier]
CVR Partners’ fertilizer plant is located in Coffeyville, Kansas, adjacent to the refinery owned by CVR Refining (NYSE: CVRR). CVR Energy (NYSE: CVI), majority-owned by Carl Icahn via Icahn Enterprises (NYSE: IEP), is the general partner and owns most of the units for both CVR Partners and CVR Refining.
- [By Robert Rapier and Igor Greenwald]
Some MLPs have experienced huge capital appreciation. Three–Icahn Enterprises (Nasdaq: IEP), Hi-Crush Partners (NYSE: HCLP), and The Blackstone Group (NYSE: BX)–gained over 100 percent in 2013. A fourth, American Midstream Partners (NYSE: AMID) gained 96 percent for the year.
- [By Dan Dzombak]
Over the past 10 years, Icahn's investment funds have returned 273%, compared to the S&P 500's 73%. His publicly traded master limited partnership, Icahn Enterprise Partners (NASDAQ: IEP ) , has returned 1,674% since Jan. 1, 2000, versus the S&P 500's 82% return. Icahn's investment funds returned all outside capital in 2011. Icahn Enterprise Partners is now the only way to get access to Icahn's investment funds, though Icahn owns 88% of the MLP.
No comments:
Post a Comment